Back to Search
Start Over
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2022 Jun; Vol. 23 (8), pp. 991-1002. Date of Electronic Publication: 2022 May 06. - Publication Year :
- 2022
-
Abstract
- Introduction: Overactive bladder (OAB) is a chronic condition highly prevalent in children and causing bothersome symptoms. It is often associated with deterioration of quality of life and can be devastating for patients and their families. Prompt initiation of conservative measures should be the backbone of treatment. When conservative management fails, pharmacological options must be considered.<br />Areas Covered: Although antimuscarinics are considered the mainstay of pharmacological treatment for OAB, only two agents are currently approved for the pediatric population. Oxybutynin and propiverine are discussed in this review, as well as other non-approved antimuscarinic agents and β3-agonists with related literature to substantiate their use in children. Dual therapy along with medication adherence and persistence is also discussed.<br />Expert Opinion: The treatment of OAB in children is demanding and one must rely on a structured, stepwise approach to achieve success. Discussing conservative measures and prescribing medication is not enough. Clinicians should actively involve children and their families in the treatment, set realistic expectations, and closely monitor side effects and medication adherence to ensure maximal efficacy.
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 23
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 35500302
- Full Text :
- https://doi.org/10.1080/14656566.2022.2072212